Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/autre/prostate-cancer-screening-2nd-ed/pauler/descriptif_3215731
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3215731

Prostate Cancer Screening (2nd Ed., 2nd ed. 2009) Second Edition Current Clinical Urology Series

Langue : Anglais

Coordonnateurs : Pauler Ankerst Donna, Tangen Catherine M., Thompson Ian M.

Couverture de l’ouvrage Prostate Cancer Screening

More than one in six men will develop prostate cancer in their lifetime. In recent years there has been an explosion of information regarding PSA screening and biomarkers for the disease. In Prostate Cancer Screening, Second Edition, the world’s leading experts on prostate cancer detection update the first edition with the latest findings. The book incorporates a series of thoughtful and cutting-edge works from the world’s experts in prostate cancer screening, ranging from the current status quo of prostate cancer screening across the globe to consensus on optimal utilization of the traditional PSA and DRE tests, to cutting-edge research in new biomarkers, biomeasures, and extended risk algorithms for prostate cancer. An additional chapter covers family-based linkage analysis as well as possible pitfalls in prostate cancer biomarker evaluation studies. Timely and authoritative, Prostate Cancer Screening, Second Edition, is an essential text for urologists, oncologists and family physicians, as well as researchers in the biomarker industry who seek methods to better develop and support markers and measures of prostate cancer.

I. Trends in prostate cancer screening 1) Overview of US Prostate Cancer Trends in the Era of PSA Screening Ruth Etzioni, MD, Roman Gulati, Angela Mariotto, PhD. 2) Trends in Prostate Cancer Screening: Overview of the UK Freddie C Hamdy, MD, Richard J Bryant, MD 3) Trends in prostate cancer screening: Canada Robert K Nam, MD, Laurence H Klotz, MD 4) Trends in prostate cancer screening: Europe Sanjai Addla, FRCS, Robert Djavan, MD, PhD II. Prostate Specific Antigen 5) Evolution of Prostate Specific Antigen for screening Javier Hernandez, MD, MS, Edith Canby-Hagino, MD, MS 6) The performance characteristics of prostate specific antigen for prostate cancer screening Ian M. Thompson, MD, Donna P. Ankerst, PhD 7) The performance of PSA after a prior negative prostate biopsy Catherine M Tangen, Dr. PH 8) Subfractions and derivatives of total prostate specific antigen in the early detection of prostate cancer Alexander Haese, MD, PhD, Alan W Partin, MD, PhD 9) PSA velocity at presentation as a predictor of prostate cancer aggressiveness Jason A Efstathiou, MD, PhD, Anthony D’Amico, MD, PhD III. Risk assessment for prostate cancer 10) Nomograms for prostate cancer Shahrokh F Shariat, MD, Mike W Kattan, MD 11) Artificial neural networks for optimizing prostate cancer risk prediction Felix K.-H. Chun, MD, Pierre I. Karakiewicz, MD 12) Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator Donna P Ankerst, PhD, Ian M Thompson, MD 13) Integration of risk assessment in prostate cancer screening Kadee Thompson, MD, Amanda Reed, MD, Dipen J Parekh, MD 14) Family history ofprostate cancer during rapidly increasing incidence Kari Hemminki, MD, Justo Lorenzo Bermelo, MD IV. Recent biomarkers for prostate cancer 15) PSA Isoforms:[-2]proPSA Significant Adjunct to Free PSA Jeffrey E Tam 16) PCA3 Jack Groskopf, PhD, Jack Schalken, PhD, Harry Rittenhouse, PhD 17) Transcriptional profiling for prostate cancer biomarker identification and clinical applications Nigel Clegg, PhD, Peter S Nelson, MD 18) Biomarkers for prostate cancer detection: family-based linkage analysis and case-control association studies Joke Beuten, Teresa L Johnson-Pais. 19) GSTP1 hypermethylation for prostate cancer detection Rui Henrique, MD, PhD, Carmen Jeronimo, PhD 20) EPCA and EPCA-2 as potential biomarkers for prostate cancer detection Eddy S Leman, PhD, Robert H Getzenberg, PhD V. Design and methodologic considerations in biomarker studies 21) Towards a robust system for biomarker triage and validations—EDRN experience Ziding Feng, PhD 22) Statistical evaluation of markers and risk tools for prostate cancer classification and prediction Yingye Zheng, PhD, Donna P Ankerst, PhD 23) Pitfalls in prostate cancer biomarker evaluation studies Donna P Ankerst, PhD VI. Building upon recently completed and ongoing prospective trials 24) Prostate-specific antigen and its role on the Prostate Cancer Prevention Trial Catherine M Tangen, Dr. PH, Phyllis Goodman, MS 25) The selenium and vitamin E cancer prevention trial Eric A Klein, MD, Catherine M Tangen, Dr. PH 26) PLCO: A randomized controlled screening trial for prostate, lung, colorectal and ovarian cancer Amanda Black, PhD, E David Crawford, MD, Robert L Grubb,

Comprehensively reviews every aspect of prostate cancer screening, including the latest discoveries in biomarker research

Outlines current screening policies by continent and presents the relative ongoing prospective screening trials around the globe

Date de parution :

Ouvrage de 397 p.

17.8x25.4 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

Prix indicatif 232,09 €

Ajouter au panier

Date de parution :

Ouvrage de 556 p.

17.8x25.4 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

Prix indicatif 232,09 €

Ajouter au panier
En continuant à naviguer, vous autorisez Lavoisier à déposer des cookies à des fins de mesure d'audience. Pour en savoir plus et paramétrer les cookies, rendez-vous sur la page Confidentialité & Sécurité.
FERMER